Efficacy of Aprepitant in Patients with Advanced or Recurrent Lung Cancer Receiving Moderately Emetogenic Chemotherapy

• Published in: Asian Pacific journal of cancer prevention : APJCP Vol. 13; no. 8; pp. 4187 - 4190
• Main Authors: Uchino, Junji, Hirano, Ryosuke, Tashiro, Naoki, Yoshida, Yuji, Ushijima, Shinichiro, Matsumoto, Takemasa, Ohta, Keiichi, Nakatomi, Keita, Takayama, Koichi, Fujita, Masaki, Nakanishi, Yoichi, Watanabe, Kentaro
• Format: Journal Article
• Language: Korean
• Published: 2012
• Subjects: CINV; aprepitant; complete suppression rate of nausea; food intake
• ISSN: 1513-7368; 2476-762X

Aims and Background: To evaluate the efficacy of a combination of aprepitant and conventional antiemetic therapy in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy (MEC). Methods: Patients with advanced or recurrent lung cancer who were treated with MEC regimens at the Department of Respiratory Medicine, Fukuoka University Hospital, were included and classified into the following groups: control group (treatment: 5-HT3 receptor antagonists + dexamethasone) and aprepitant group (treatment: 5-HT3 receptor antagonists + dexamethasone + aprepitant). The presence or absence of chemotherapy-induced nausea and vomiting (CINV) was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0; patients with grade 1 or above were considered positive for CINV. Food intake per day, completion of planned chemotherapy, and progression-free survival (PFS) achieved by chemotherapy were investigated. Results: The complete suppression rate of nausea in the aprepitant group was significantly higher than that in the control group (p = 0.0043). Throughout the study, the food intake in the aprepitant group was greater than that in the control group, with the rate being significantly higher, in particular, on day 5 (p = 0.003). The completion rate of planned chemotherapy was also higher in the aprepitant group (p = 0.042). PFS did not differ significantly, but tended to be improved in the aprepitant group. Conclusions: The aprepitant group showed significantly higher complete suppression of nausea, food intake on day 5, and completion of planned chemotherapy than the control group.